Financial PerformanceCartesian reported a net loss of $1.13 per share, which was higher than the estimated net loss of $0.90 per share.
Stock Price TargetThe price target for Cartesian has been adjusted down to $41 per share, indicating a reduction from the previous target.
Therapeutic ChallengesDM represents a tough indication where therapeutics have faced challenges, including Kezar's KZR-616, which did not meet its primary endpoint.